Advanced Enzyme Technologies Approves ₹69.7 Crore Open-Market Buyback

Q1 FY27 Consolidated Results YoY: Revenue at 190 Cr vs 186 Cr, up 2.1%. EBITDA at 64.0 Cr vs 65.3 Cr, down 2.0%. EBITDA Margin at 33.7% vs 35.1%, contraction of 140bps; cost of materials grew 24.0% vs revenue growth of 2.1%. PAT at 38.6 Cr vs 40.4 Cr, down 4.6%. Board approved an open-market buyback of up to 69.7 Cr at a maximum price of Rs 500 per share, representing up to 1.24% of equity. The company also approved acquiring the remaining 4.28% of JC Biotech for 8.0 Cr, making it wholly owned, and funding Advanced Nutrazyme with up to 2.0 Cr.